Invitae (NYSE:NVTA) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

NYSE:NVTA opened at $0.00 on Friday. Invitae has a 12 month low of $0.02 and a 12 month high of $0.02. The firm’s 50 day moving average is $0.01 and its 200 day moving average is $0.26. The stock has a market capitalization of $213,608.00, a PE ratio of 0.00 and a beta of 1.59.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its holdings in shares of Invitae by 90.7% in the 4th quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after purchasing an additional 43,717 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Invitae by 404.6% during the 3rd quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 50,600 shares in the last quarter. Financial Gravity Asset Management Inc. lifted its holdings in shares of Invitae by 1,799.5% during the third quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 70,037 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Invitae by 14.1% in the third quarter. HighTower Advisors LLC now owns 600,354 shares of the medical research company’s stock worth $339,000 after purchasing an additional 74,405 shares during the last quarter. Finally, Pathstone Family Office LLC grew its stake in shares of Invitae by 94.2% during the 3rd quarter. Pathstone Family Office LLC now owns 157,972 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 76,639 shares during the period. Institutional investors own 61.28% of the company’s stock.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.